Soluble interleukin-6 receptor as a prognostic factor in multiple myeloma

British Journal of Haematology

Volumn 92, Issue 2, 1996, Pages 370-374

  Pulkki, Kari ^a   Pelliniemi, Tarja Terttu ^a   Rajamäki, Allan ^a   Tienhaara, Anri ^a   Laakso, Markku ^b   Lahtinen, Reino ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Beta 2 microglobulin; Interleukin 6; Interleukin 6 receptor; Multiple myeloma; Survival

Indexed keywords

BETA 2 MICROGLOBULIN; CLODRONIC ACID; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; MELPHALAN; PREDNISONE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0030057701     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1996.d01-1470.x     Document Type: Article

References (22)

1. Bataille, R., Boccadoro, M., Klein, B., Durie,. B. & Pileri, A. (1992) C-reactive protein and β-2 microglobulin produce a simple and powerful myeloma staging system. Blood, 80, 733-737.
2. Bataille, R., Jourdan, M., Zhang, X.-G. & Klein, B. (1989) Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation, 84, 2008-2011.
3. Cox, D.R. (1972) Regression models and life tables (with discussion). Journal of the Royal Statistical Society B, 34, 187-220.
4. Durie, B.G.M. & Salmon, S.E. (1975) A clinical staging system for multiple myeloma. Cancer, 36, 842-857.
5. Gaillard, J.-P., Bataille, R., Brailly, H., Zuber, C., Yasukawa, K., Attal, M., Maruo, N., Taga, T., Kishimoto, T. & Klein, B. (1993) Increased and highly stable levels of functional soluble interleukin-6 receptor in sera of patients with monoclonal gammopathy. European Journal of Immunology, 23, 820-824.
6. Greipp,. R.P., Gaillard, J.P., Klein, B., Oken, M.M., Kalish, L., Leong, T. & Kyle, R.A. (1994) Independent prognostic value for plasma cell labeling index (PCLI), immunofluorescence microscopy plasma cell percent (IMPCP), beta 2-microglobulin (β2M), soluble interleukin-6 receptor (sIL-6R), and C-reactive protein (CRP) in myeloma trial E9487. (Abstract). Blood, 84, (Suppl. 1), 385a.
7. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A. & Kishimoto, T. (1988) Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature, 332, 83-85.
8. Kishimoto, T., Akira, T. & Taga, T. (1992) Interleukin-6 and its receptor-A paradigm for cylokines. Science, 258, 593-597.
9. Kishimoto, T., Taga, T. & Akira, S. (1994) Cytokine signal transduction. Cell, 76, 253-262.
10. Klein, B. & Bataille, R. (1992) Cytokine network in human multiple myeloma. Hematology/Oncology Clinics of North America, 6, 273-284.
11. Klein, B., Zhang, X.-G., Jourdan, M., Content, J., Houssiau, F., Aarden, L., Piechaczyk, M. & Bataille, R. (1989) Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood, 73, 517-526.
12. Kyle, R.A. (1994) Why better prognostic factors for multiple myeloma are needed. Blood, 83, 1713-1716.
13. Lahtinen, R., Laakso, M., Palva, I., Virkkunen, P. & Elomaa, I. (1992) Randomised, placebo-controlled multicentre trial of clodronate in multiple myeloma. Lancet, ii, 1049-1052.
14. Ludwig, H., Nachbaur, D.M., Fritz, E., Krainer, M. & Huber, H. (1991) Interleukin-6 is a prognostic factor in multiple myeloma. (Letter). Blood, 77, 2794-2795.
15. Lust, J.A., Donovan, K.A., Kline, M.P., Greipp, P.R. & Kyle, R.A. (1992) Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine, 4, 96-100.
16. Merlini, C., Perfetti, V., Gobbi, P.G., Quaglini, S., Franciotta, D.M., Marinone, G. & Ascari, E. (1993) Acute phase proteins and prognosis in multiple myeloma. British Journal of Haematology, 83, 595-601.
17. Mullberg, J., Dittrich, E., Graeve, L., Gerhartz, C., Yasukawa, K., Taga, T., Kishimoto, T., Heinrich, P.C. & Rose-John, S. (1993) Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Letters, 332, 174-178.
18. Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koshihara, Y., Yancopoulos, G.D., Taga, T. & Kishimoto, T. (1993) Soluble forms of interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood, 82, 1120-1126.
19. Pelliniemi, T.-T., Irjala, K., Mattila, K., Pulkki, K., Rajamäki, A., Tienhaara, A., Laakso, M. & Lahtinen, R. (1995) Immunoreactive interleukin-6 and acute phase proteins as prognostic factors in multiple myeloma. Blood, 85, 765-771.
20. Pulkki, K., Pelliniemi, T.-T., Irjala, K., Mattila, K., Rajamaki, A., Tienhaara, A., Laakso, M. & Lahtinen, R., for the Finnish Leukaemia Group (1994) High levels of soluble interleukin-6 receptor (sIL-6R) and immunoreactive interleukin-6 (IL-6) predict poor prognosis in multiple myeloma (MM). (Abstract). Blood, 84, (Suppl. 1), 385a.
21. Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T. & Kishimoto, T. (1989) Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell, 58, 573-581.
22. Yasukawa, K., Futatsugi, K., Saito, T., Yawata, H., Narazaki, M., Suzuki, H., Taga, T. & Kishimoto, T. (1992) Association of recombinant soluble IL-6-signal transducer, gp130, with a complex of IL-6 and soluble IL-6 receptor, and establishment of an ELISA for soluble gp130. Immunology Letters, 31, 123-130.